
Supplementary information

Sensitivity of SARS-CoV-2 B.1.1.7 to mRNA vaccine-elicited antibodies

In the format provided by the
authors and unedited

Table 1: Neutralization, V gene usage and other properties of tested mAbs.

mAb	Domain (site)	VH usage (% id.)	Source (DSO)	IC50 WT (ng/ml)	IC50 B.1.1.7 (ng/ml)	ACE2 blocking	SARS-CoV	Escape residues	Ref.
4A8	NTD (i)	1-24	N/A	38	-	Neg.	-	S12P; C136Y; Y144del; H146Y; K147T; R246A	⁵⁰
S2L26	NTD (i)	1-24 (97.2)	Hosp. (52)	70	-	Neg.	-	N/A	²⁴
S2L50	NTD (i)	4-59 (95.4)	Hosp. (52)	264	50	Neg.	-	N/A	²⁴
S2M28	NTD (i)	3-33 (97.6)	Hosp. (46)	295	12'207	Neg.	-	P9S/Q; S12P; C15F/R; L18P; Y28C; A123T; C136Y; G142D; Y144del; K147Q/T; R246G; P251L; G252C	²⁴
S2X107	NTD (i)	4-38-2 (97)	Sympt. (75)	388	-	Neg.	-	N/A	²⁴
S2X124	NTD (i)	3-30 (99)	Sympt. (75)	221	-	Neg.	-	N/A	²⁴
S2X158	NTD (i)	1-24 (96.3)	Sympt. (75)	56	-	Neg.	-	N/A	²⁴
S2X28	NTD (i)	3-30 (97.9)	Sympt. (48)	1'399	-	Neg.	-	P9S; S12P; C15W; L18P; C136G/Y; F140S; L141S; G142C/D; Y144C/N; K147T/Q/E; R158G; L244S; R246G	²⁴
S2X303	NTD (i)	2-5 (95.9)	Sympt. (125)	69	-	Neg.	-	N/A	²⁴
S2X333	NTD (i)	3-33 (96.5)	Sympt. (125)	66	-	Neg.	-	P9L; S12P; C15S/Y; L18P; C136G/Y; F140C; G142D; K147T	²⁴
S2D106	RBD (I/RBM)	1-69 (97.2)	Hosp. (98)	27	20	Strong	-	N/A	⁸
S2D19	RBD (I/RBM)	4-31 (99.7)	Hosp. (49)	128	75'200	Moderate	-	N/A	⁸
S2D32	RBD (I/RBM)	3-49 (98.3)	Hosp. (49)	26	11	Strong	-	N/A	⁸
S2D65	RBD (I/RBM)	3-9 (96.9)	Hosp. (49)	24	12	Weak	-	N/A	⁸
S2D8	RBD (I/RBM)	3-23 (96.5)	Hosp. (49)	27	58'644	Strong	-	N/A	⁸
S2D97	RBD (I/RBM)	2-5 (96.9)	Hosp. (98)	20	17	Weak	-	N/A	⁸
S2E11	RBD (I/RBM)	4-61 (98.3)	Hosp. (51)	27	16	Weak	-	N/A	⁸
S2E12	RBD (I/RBM)	1-58 (97.6)	Hosp. (51)	27	31	Strong	-	G476S (3x)	^{8,51}
S2E13	RBD (I/RBM)	1-18 (96.2)	Hosp. (51)	34	77	Strong	-	N/A	⁸
S2E16	RBD (I/RBM)	3-30 (98.3)	Hosp. (51)	36	38	Strong	-	N/A	⁸
S2E23	RBD (I/RBM)	3-64 (96.9)	Hosp. (51)	139	180	Strong	-	N/A	⁸
S2H14	RBD (I/RBM)	3-15 (100)	Sympt. (17)	460	64'463	Weak	-	N/A	^{8,52}
S2H19	RBD (I/RBM)	3-15 (98.6)	Sympt. (45)	239	-	Weak	-	N/A	⁸
S2H58	RBD (I/RBM)	1-2 (97.9)	Sympt. (45)	27	14	Strong	-	N/A	⁸
S2H7	RBD (I/RBM)	3-66 (98.3)	Sympt. (17)	492	573	Weak	-	N/A	⁸
S2H70	RBD (I/RBM)	1-2 (99)	Sympt. (45)	147	65	Weak	-	N/A	⁸
S2H71	RBD (I/RBM)	2-5 (99)	Sympt. (45)	36	9	Moderate	-	N/A	⁸

S2M11	RBD (I/RBM)	1-2 (96.5)	Hosp. (46)	11	4	Weak	-	Y449N; L455F; E484K; E484Q; F490L; F490S; S494P	^{8,51}
S2N12	RBD (I/RBM)	4-39 (97.6)	Hosp. (51)	76	40	Strong	-	N/A	⁸
S2N22	RBD (I/RBM)	3-23 (96.5)	Hosp. (51)	32	21	Strong	-	N/A	⁸
S2N28	RBD (I/RBM)	3-30 (97.2)	Hosp. (51)	72	21	Strong	-	N/A	⁸
S2X128	RBD (I/RBM)	1-69-2 (97.6)	Sympt. (75)	50	112	Strong	-	N/A	⁸
S2X16	RBD (I/RBM)	1-69 (97.6)	Sympt. (48)	45	103	Strong	-	N/A	⁸
S2X192	RBD (I/RBM)	1-69 (96.9)	Sympt. (75)	326	-	Weak	-	N/A	⁸
S2X227	RBD (I/RBM)	1-46 (97.9)	Sympt. (75)	26	14	Strong	-	N/A	
S2X246	RBD (I/RBM)	3-48 (96.2)	Sympt. (75)	35	30	Strong	-	N/A	
S2X30	RBD (I/RBM)	1-69 (97.9)	Sympt. (48)	32	53	Strong	-	N/A	⁸
S2X324	RBD (I/RBM)	2-5 (97.3)	Sympt. (125)	8	23	Strong	-	N/A	
S2X58	RBD (I/RBM)	1-46 (99)	Sympt. (48)	32	47	Strong	-	N/A	⁸
S2H90	RBD (II)	4-61 (96.6)	Sympt. (81)	77	32	Strong	+	N/A	⁸
S2H94	RBD (II)	3-23 (93.4)	Sympt. (81)	123	144	Strong	+	N/A	⁸
S2H97	RBD (V)	5-51 (98.3)	Sympt. (81)	513	248	Weak	+	N/A	
S2K15	RBD (II)	2-26 (99.3)	Sympt. (87)	361	235	0	+	N/A	
S2K21	RBD (II)	3-33 (96.2)	Sympt. (118)	201	189	0	+	N/A	
S2K30	RBD (II)	1-2 (97.2)	Sympt. (87)	185	134	0	+	N/A	
S2K63v2	RBD (II)	3-30-3 (95.6)	Sympt. (118)	144	215	0	+	N/A	
S2L17	RBD (?)	5-10-1 (98.3)	Hosp. (51)	313	127	Moderate	+	N/A	⁸
S2L49	RBD (?)	3-30 (97.9)	Hosp. (51)	24	32	Neg.	+	N/A	⁸
S2X259	RBD (IIa)	1-69 (94.1)	Sympt. (75)	145	91	Moderate	+	N/A	
S2X305	RBD (?)	1-2 (95.1)	Sympt. (125)	34	21	Strong	-	N/A	
S2X35	RBD (IIa)	1-18 (98.6)	Sympt. (48)	140	143	Strong	+	N/A	⁵²
S2X450	RBD (?)	2-26 (96.9)	Sympt. (271)	368	198	Strong	+	N/A	
S2X475	RBD (?)	3-21 (93.8)	Sympt. (271)	1'431	851	Strong	+	N/A	
S2X607	RBD (?)	3-66 (95.4)	Sympt. (271)	41	23	Strong	-	N/A	
S2X608	RBD (?)	1-33 (93.2)	Sympt. (271)	21	35	Strong	-	N/A	
S2X609	RBD (?)	1-69 (93.8)	Sympt. (271)	47	35	Strong	-	N/A	
S2X613	RBD (I)	1-2 (91.7)	Sympt. (271)	28	19	Strong	-	N/A	
S2X615	RBD (I)	3-11 (94.8)	Sympt. (271)	23	17	Strong	-	N/A	
S2X619	RBD (?)	1-69 (92.7)	Sympt. (271)	36	60	Strong	-	N/A	
S2X620	RBD (?)	3-53 (95.1)	Sympt. (271)	34	45	Strong	-	N/A	

id., identity. DSO, days after symptom onset. * as described in Piccoli et al and McCallum et al. N/A, not available; -, not neutralising.